ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO1049

Dose-Dependent Nephroprotective Effects of an ALK5 Inhibitor in the Unilateral Ureteral Obstruction (UUO) Mouse Model of Kidney Fibrosis

Session Information

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms


  • Bak, Stine Thorhauge, Gubra, Hoersholm, Denmark
  • Nøhr-Meldgaard, Jacob, Gubra, Hoersholm, Denmark
  • Jensen, Ditte Marie, Gubra, Hoersholm, Denmark
  • Rune, Ida, Gubra, Hoersholm, Denmark
  • Sembach, Frederikke Emilie, Gubra, Hoersholm, Denmark
  • Frias Hernandez, Alex, Gubra, Hoersholm, Denmark
  • Secher, Thomas, Gubra, Hoersholm, Denmark
  • Ougaard, Maria Katarina, Gubra, Hoersholm, Denmark
  • Christensen, Michael, Gubra, Hoersholm, Denmark

Development of renal fibrosis is a hallmark of chronic kidney disease (CKD) and an essential factor for progressive loss of kidney function and development of end-stage kidney disease. The unilateral ureteral obstruction (UUO) mouse is a widely used surgery-induced model of CKD with rapid induction of renal inflammation and fibrosis. Here, we characterized the effect of an anti-fibrotic TGF-β type 1 receptor kinase inhibitor (ALK5 inhibitor, ALK5i) on renal outcomes in the UUO mouse.


Male C57BL/6J mice (9 weeks old) were randomised into study groups based on body weight and were either sham-operated or underwent UUO surgery. UUO mice received vehicle or ALK5i (3, 10 or 30 mg/kg, PO, BID) for 8 days. Vehicle-dosed sham-operated mice served as controls. At termination, both kidneys were weighed, and the obstructed left kidney was processed for quantitative histological assessment of macrophage infiltration (F4/80), fibrosis (Col1a1, Col3a1), myofibroblast activation (α-SMA) and tubular injury (KIM-1). Plasma was sampled for measurement of KIM-1 levels.


UUO mice displayed marked kidney tubular injury, macrophage infiltration, myofibroblast activation, and fibrosis as compared to sham-operated animals. ALK5i dose-dependently improved kidney histology and plasma KIM-1 levels.


ALK5i exerted dose-dependent nephroprotective effects in the UUO mouse. Given the rapid induction of fibrosis and inflammation, the UUO mouse is optimal for screening of compounds with potential anti-inflammatory and anti-fibrotic effects.


  • Commercial Support – Gubra